RCS - PureTech Health PLC - PRTC's Seaport Adds Finance/Operations Exec to BOD

Puretech HealthAnnouncement

11/03/2025 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250311:nRSK0915Aa&default-theme=true

RNS Number : 0915A  PureTech Health PLC  11 March 2025

11 March 2025

PureTech Health plc

 

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its
Board of Directors as Audit Committee Chair

 

Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of
biotech financial and operational experience

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted
that its Founded Entity, Seaport Therapeutics (https://seaporttx.com/) ,
("Seaport") a clinical-stage biopharmaceutical company that is advancing novel
neuropsychiatric medicines with a proven strategy and team, today announced
that Robert "Bob" J. Hombach has been appointed to its Board of Directors and
will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned
financial and operational executive with three decades of high-level
leadership in the healthcare sector. His experience includes serving on the
Audit, Finance and Compensation Committees for several public and private
Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ:
BMRN), where he also chairs the Audit Committee, and Henry Schein (NASDAQ:
HSIC), a member of the S&P 500® index.

 

The full text of the announcement from Seaport is as follows:

 

Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as
Audit Committee Chair

 

Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of
biotech financial and operational experience

 

BOSTON, March 11, 2025 - Seaport Therapeutics (https://seaporttx.com/)
("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that
is advancing novel neuropsychiatric medicines with a proven strategy and team,
today announced that Robert "Bob" J. Hombach has been appointed to its Board
of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach
is a seasoned financial and operational executive with three decades of
high-level leadership in the healthcare sector. His experience includes
serving on the Audit, Finance and Compensation Committees for several public
and private Boards of Directors, such as FORTUNE 500 companies like BioMarin
(NASDAQ: BMRN), where he also chairs the Audit Committee, and Henry Schein
(NASDAQ: HSIC), a member of the S&P 500® index.

 

"We are excited to add Bob to our board. His financial and operational
expertise perfectly complements the outstanding group of industry leaders on
our board," said Daphne Zohar, Founder and Chief Executive Officer of Seaport
Therapeutics. "His deep understanding of the financial and operational
intricacies of growing biotech companies will be an asset to Seaport as we
advance our pipeline through important milestones, with the goal of delivering
potentially life-changing neuropsychiatric medicines to patients and their
families."

 

Mr. Hombach served as the Executive Vice President, Chief Financial Officer
and Chief Operations Officer of Baxalta (NYSE: BXLT), a $6 billion global
biopharmaceutical company, until it was acquired by Shire plc. in 2016. He was
instrumental in Baxalta's successful spin off from its parent company, Baxter
(NYSE: BAX), a nearly $18 billion company, where he previously served as
Corporate Vice President and Chief Financial Officer. While at Baxter, he led
the company's strategic restructuring process and oversaw its venture capital
investments through the Baxter Ventures Fund. In addition to his board
positions at BioMarin and Henry Schein, Mr. Hombach is the Chair of the Audit
Committee at Embecta (NASDAQ: EMBC), a global diabetes care company spun out
of Becton Dickinson, and has held previous board positions at several other
companies including Naurex, Inc., which was acquired by Allergan in 2015.

 

"Seaport is a new breed of company that is in a unique position to change the
lives of patients with depression and anxiety disorders, and I am honored to
contribute to the Company's growth at such a pivotal time," said Mr. Hombach.
"Seaport's scientific approach to advancing neuropsychiatric medicines is
exciting and differentiated, and I look forward to supporting the Company's
commitment to maintaining the highest standards of financial oversight and
governance as it continues its mission to make a difference in the lives of
patients and their families impacted by these conditions."

 

Mr. Hombach has earned numerous accolades, including recognition by IR
Magazine as a Top 100 US CFO ranked seventh in both 2013 and 2014. He was also
honored as a Board Leadership Fellow by the National Association of Corporate
Directors (NACD). Mr. Hombach holds an M.B.A. from Northwestern University's
J.L. Kellogg Graduate School of Management and a B.S. in Finance cum laude
from the University of Colorado.

 

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing
the development of novel neuropsychiatric medicines in areas of high unmet
patient needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are overcome
with its proprietary Glyph(TM) technology platform. All the therapeutic
candidates in its pipeline of first and best-in-class medicines are based on
the Glyph platform, which is uniquely designed to enable oral bioavailability,
bypass first-pass metabolism and reduce liver enzyme elevations or
hepatotoxicity and other side effects. Seaport is led by an experienced team
that invented and advanced important neuropsychiatric medicines and are guided
by an extensive network of renowned scientists, clinicians and key opinion
leaders. For more information, please visit www.seaporttx.com
(http://www.seaporttx.com/) .

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of therapeutic
candidates were initially identified or discovered and then advanced by the
PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com) or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to Seaport's development plans for
its pipeline of neuropsychiatric therapeutics based on the Glyph Platform, the
applicability of the platform beyond neuropsychiatry, potential benefits to
patients, and Seaport's and our future prospects, developments and strategies.
The forward-looking statements are based on current expectations and are
subject to known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited to, those
risks, uncertainties and other important factors described under the caption
"Risk Factors" in our Annual Report on Form 20-F for the year ended December
31, 2023, filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in which it will
operate in the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information, future
events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Justin Chen

+1 609 578 7230

justin@tenbridgecommunications.com (mailto:justin@tenbridgecommunications.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEDEFALSEAA